Fennec Pharmaceuticals (TSE:FRX) Reaches New 12-Month High - Time to Buy?

Key Points

• Fennec Pharmaceuticals reached a new 52-week high of C$12.99 during trading, with a market cap of C$361.54 million.
• The company is developing Sodium Thiosulfate (STS) to prevent cisplatin-induced hearing loss in children, with its lead product candidate being PEDMARK.
• Insider sales totaled 13,246 shares valued at C$137,297 in the last 90 days, highlighting significant activity among directors.

Fennec Pharmaceuticals Inc. (TSE:FRX - ) reached a new 52-week high during trading on Tuesday . The company traded as high as C$12.99 and last traded at C$12.99, with a volume of 3154 shares trading hands. The stock had previously closed at C$12.59.

Fennec Pharmaceuticals Price Performance

The business has a 50-day simple moving average of C$11.94 and a 200 day simple moving average of C$10.52. The stock has a market cap of C$361.54 million, a P/E ratio of -28.87 and a beta of 2.09. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.

Insider Activity at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov sold 10,000 shares of the company's stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of C$11.71, for a total value of C$117,096.00. In the last 90 days, insiders sold 13,246 shares of company stock valued at $137,297. Insiders own 16.20% of the company's stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.